ICD-10-CM Billable Code

M34.1

CR(E)ST syndrome

Clinical Classification Guidelines

Inclusion Terms

  • Combination of calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia

Medical Intelligence & Overview

CREST syndrome is a subtype of systemic sclerosis, a long-term autoimmune disease that affects the skin and internal organs. Named after its characteristic features, CREST syndrome is a rare condition that involves a combination of specific clinical signs, including calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia. The syndrome can vary significantly in severity among individuals, influencing the types of symptoms experienced and the approach to management. Proper understanding of CREST syndrome is essential for early recognition and appropriate medical attention.

Causes & Symptoms

Clinical Causes: The exact cause of CREST syndrome remains unknown. It involves an abnormal immune response, where the immune system mistakenly attacks healthy tissues. Genetic factors may predispose some individuals to develop the syndrome. Environmental exposures, such as certain chemicals or substances, might contribute to its development. Viral or bacterial infections are also considered potential triggers in susceptible individuals.

Key Symptoms: Calcinosis: Formation of calcium deposits under the skin, often appearing as hard lumps. Raynaud's phenomenon: Episodes where fingers and toes turn white or blue in response to cold or stress, often accompanied by numbness or tingling. Esophageal dysfunction: Difficulty swallowing, acid reflux, or heartburn due to esophageal smooth muscle involvement. Sclerodactyly: Thickening and tightening of the skin on the fingers and toes, leading to limited mobility. Telangiectasia: Visible small blood vessels appearing as red or purple spots on the skin, usually on the face, hands, or lips.

Diagnostic & Treatment

Diagnosis Path: Diagnosis of CREST syndrome primarily involves clinical evaluation, including detailed medical history and physical examination focusing on characteristic features. Additional tests may include blood tests for specific antibodies related to systemic sclerosis, such as anti-centromere antibodies, which are often positive in CREST syndrome. Imaging studies like X-rays can assess calcinosis, and esophageal studies might include manometry or endoscopy to evaluate esophageal function. Skin biopsy, although less common, can sometimes support the diagnosis by revealing characteristic skin changes.

Treatment Protocols: While there is no cure for CREST syndrome, various treatment strategies aim to manage symptoms and prevent complications. Treatment approaches are tailored to the individual's specific manifestations and severity, and may include: - Medications to improve blood flow, such as calcium channel blockers, to reduce the severity of Raynaud's episodes. - Drugs that suppress immune activity, such as immunosuppressants, for severe skin or organ involvement. - Pain management and wound care for calcinosis lesions. - Proton pump inhibitors or other reflux medications to treat esophageal symptoms. - Regular monitoring and supportive therapies to prevent complications like lung or kidney issues. Multidisciplinary care involving rheumatologists, dermatologists, and other specialists is often essential for comprehensive management.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is M34.1 a billable ICD-10 code?
Yes, M34.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report M34.1?
Clinical documentation must specify the nature of CR(E)ST syndrome and any associated comorbidities for accurate reporting.

Cite this Clinical Reference

Related Diagnosis Codes

Clinical Meta Tags

syndrome